Literature DB >> 10068094

Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity.

H Zylberberg1, A C Rimaniol, S Pol, A Masson, D De Groote, P Berthelot, J F Bach, C Bréchot, F Zavala.   

Abstract

BACKGROUND/AIMS: Tumor necrosis factor-alpha (TNF) is a mediator of inflammation and cellular immune response. Soluble TNF receptors (sTNFR) sTNF-R55 and sTNF-R75, which compete with cellular receptors for the binding of TNF, have been detected at high levels in infectious diseases including human immunodeficiency virus and HBV infection. In order to investigate the activation of the TNF system in HCV infection, we have analyzed the balance between TNF and sTNF-R in 60 HCV-infected subjects according to their clinical, biological, virological and histological characteristics.
METHODS: Serum TNF, sTNF-R55 and sTNF-R75 levels were determined by ELISA before any therapy and were compared to a control group of 60 healthy subjects and a group of 34 HBV-infected patients.
RESULTS: Mean TNF levels were 50.5+/-4.5 pg/ml in HCV patients, and undetectable (<5 pg/ml) in the control subjects. sTNF-R55 and sTNF-R75 levels were significantly higher in HCV-infected patients than in the controls: 2.88+/-0.14 ng/ml vs. 1.30+/-0.05, (p = 0.0001), and 9.54+/-0.58 ng/ml vs. 4.19+/-016, (p = 0.0001), respectively. sTNF-R55 and TNF-alpha levels in HCV patients were not significantly different from levels in HBV patients. sTNF-R75 levels were slightly lower than in HBV patients (9.54+/-0.58 vs. 11.4+/-0.79 ng/ml, p = 0.03). In contrast to other infectious diseases, there was no correlation between levels of sTNF-R and TNF. sTNF-R75 but not TNF levels were correlated with aminotransferases levels (p = 0.0001 and p = 0.0015 for aspartate and alanine aminotransferase, respectively), while sTNF-R55 levels were significantly correlated only with aspartate aminotransferase levels (p = 0.003). sTNF-R75 levels were significantly correlated with the Metavir activity index (p = 0.01), and sTNF-R55 and sTNF-R75 levels were significantly higher in patients with vs. without cirrhosis (3.22+/-0.21 vs. 2.54+/-0.17 ng/ml (p<0.02) and 11.6+/-0.86 vs. 7.5+/-0.53 ng/ml (p<0.001), respectively). sTNF-R55, sTNF-R75 and TNF levels were not correlated with viral load, genotype or response to interferon therapy.
CONCLUSIONS: Levels of soluble TNF receptors, and particularly sTNF-R75, are significantly correlated with the severity of the disease but not with virological parameters such as quantitative viremia and genotype. High TNF-R production could thus suggest that HCV-related liver disease involves immunological mechanisms, including activation of the TNF system.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10068094     DOI: 10.1016/s0168-8278(99)80060-9

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  33 in total

1.  Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin.

Authors:  F Torre; S Rossol; N Pelli; M Basso; A Delfino; A Picciotto
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

2.  Hepatitis C virus treatment complicated by rheumatoid arthritis.

Authors:  Meredith Borman; Mark G Swain
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

Review 3.  Hepatitis C as a systemic disease: virus and host immunologic responses underlie hepatic and extrahepatic manifestations.

Authors:  Chiaki Okuse; Hiroshi Yotsuyanagi; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2007-11-22       Impact factor: 7.527

4.  Hepatitis C virus infection and pain sensitivity in patients on methadone or buprenorphine maintenance therapy for opioid use disorders.

Authors:  Judith I Tsui; Marlene C Lira; Debbie M Cheng; Michael R Winter; Daniel P Alford; Jane M Liebschutz; Jianren Mao; Robert R Edwards; Jeffrey H Samet
Journal:  Drug Alcohol Depend       Date:  2015-05-22       Impact factor: 4.492

5.  Bone Mineral Density, Bone Turnover, and Systemic Inflammation in Non-cirrhotics with Chronic Hepatitis C.

Authors:  Jennifer C Lai; Dolores M Shoback; Jacob Zipperstein; Blanca Lizaola; Samuel Tseng; Norah A Terrault
Journal:  Dig Dis Sci       Date:  2015-01-07       Impact factor: 3.199

6.  Chronic Hepatitis C Virus Infection and the Proinflammatory Effects of Injection Drug Use.

Authors:  Martin Markowitz; Sherry Deren; Charles Cleland; Melissa La Mar; Evelyn Silva; Pedro Batista; Leslie St Bernard; Natanya Gettie; Kristina Rodriguez; Teresa H Evering; Haekyung Lee; Saurabh Mehandru
Journal:  J Infect Dis       Date:  2016-08-11       Impact factor: 5.226

7.  Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients.

Authors:  Sophia Li; Primal P Kaur; Virginia Chan; Steven Berney
Journal:  Clin Rheumatol       Date:  2009-03-17       Impact factor: 2.980

8.  LCMV-mediated hepatitis in rhesus macaques: WE but not ARM strain activates hepatocytes and induces liver regeneration.

Authors:  I S Lukashevich; J D Rodas; I I Tikhonov; J C Zapata; Y Yang; M Djavani; M S Salvato
Journal:  Arch Virol       Date:  2004-08-30       Impact factor: 2.574

Review 9.  Hepatitis C virus infection and apoptosis.

Authors:  Richard Fischer; Thomas Baumert; Hubert-E Blum
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

10.  Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4.

Authors:  Abdel-Rahman N Zekri; Hanaa M Alam El-Din; Abeer A Bahnassy; Naglaa A Zayed; Waleed S Mohamed; Suzan H El-Masry; Sayed K Gouda; Gamal Esmat
Journal:  Comp Hepatol       Date:  2010-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.